Oral hyoscine butylbromide does not alter the pattern of small intestinal motor activity.
1. Continuous recording of proximal jejunal motility of conscious healthy subjects was made following ingestion of 200 mg hyoscine butylbromide (ten times the recommended therapeutic dosage). 2. There was no detectable modification of fasting or postprandial motor activity, although the therapeutic potency of the standard intravenous dose was confirmed.
D000284:Administration, Oral; D002086:Butylscopolammonium Bromide / Q000494:pharmacology*; D005769:Gastrointestinal Motility / Q000187:drug effects*; D006801:Humans; D007421:Intestine, Small / Q000187:drug effects*; D012602:Scopolamine Derivatives / Q000494:pharmacology*
D012602:Scopolamine Derivatives; D002086:Butylscopolammonium Bromide